Alan C. Cheng, PhD.

Adjunct Faculty, Brandeis University
Research Scientist, Amgen Inc.

 
 
    

I teach in the Brandeis Graduate Professional Studies Bioinformatics M.S. and Graduate Certificate programs.  I am also a scientist at the Amgen Cambridge research labs, where I work with chemists and biologists on the discovery of new medicines for oncology and neuroscience diseases. My scientific interests are in computer-aided drug design and biological sequence-structure relationships.

I teach:
More about me:
Selected publications   ( Click for full list) :
    Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design.   Patel SD et al.   (2009)   Bioorg Med Chem Lett.

    Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.   Cee VJ et al.   (2009)   Bioorg Med Chem Lett.

    Predicting selectivity and druggability in drug discovery.   Cheng AC.   (2008)   Annual Reports Comp Chem.

    Structure-based maximal affinity model predicts small-molecule druggability.   Cheng AC et al.   (2007)  Nature Biotechnology.

    Structure-based identification of small molecule binding sites using a free energy model.   Coleman RG et al.  (2006)  J Chem Inf Model.

    Optimal charges in lead optimization: a structure-based neuraminidase case study.   Armstrong KA et al.  (2006)  J Med Chem.

    An intuitive approach to measuring protein surface curvature.   Coleman RG et al.  (2005)  Proteins.

    Ab-initio interaction energies of amino acid side-chain hydrogen bond interactions with nucleic acid bases. Cheng AC et al.  (2004)  J Am Chem Soc.

    Recognition of nucleic acid bases and base-pairs by hydrogen bonding to amino acid side-chains.   Cheng AC et al. (2003)   J Mol Biol.